Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma

Antonella Cingolani, Rita Murri, Luigi Maria Larocca, Luciana Teofili, Lorenza Torti, Carmela Pinnetti, Katleen De Gaetano Donati, Evelina Tacconelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

32 Citazioni (Scopus)

Abstract

In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.
Lingua originaleEnglish
pagine (da-a)2408-2412
Numero di pagine5
RivistaAIDS
Volume24
DOI
Stato di pubblicazionePubblicato - 2010

Keywords

  • Adult
  • Aged
  • Drug Interactions
  • Female
  • HIV Infections
  • HIV Protease Inhibitors
  • Hodgkin Disease
  • Humans
  • Male
  • Middle Aged
  • Ritonavir
  • Vinblastine

Fingerprint Entra nei temi di ricerca di 'Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma'. Insieme formano una fingerprint unica.

Cita questo